Press releases

Language update supports the strong safety profile for PROMUS Element and PROMUS Element Plus Stents.

PLATINUM Long Lesion clinical results presented at TCT 2012 show no heart attack or stent thrombosis at two-year follow-up.

Twelve-month data presented at TCT 2012 support safety and efficacy of Epic stent in iliac stenting.

Results presented on cost effectiveness and clinical benefits for older patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System feasibility trial results reviewed.

Clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

"We remain focused on executing our strategy to drive this organization back to revenue growth,” said CEO Hank Kucheman.

REPRISE II study results expected to support CE Mark and other regulatory filings.

Victory™ guidewires are designed to facilitate crossing of resistant lesions.

Pending addition of next generation mapping and navigation system would expand company portfolio into complex electrophysiology procedures.

Learn how to tune in for the webcast or the replay.

Disorders affect nearly 30 million American women; new research shows high prevalence of patients not understanding their treatment options.

S-ICD System is the world's first and only commercially available completely subcutaneous implantable defibrillator.

S-ICD System is world's first and only commercially available completely subcutaneous implantable defibrillator.

First and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions

RELIANCE® 4-FRONT™ lead designed to streamline surgical procedure for treatment of heart failure and sudden cardiac arrest.

Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions.

New bronchial thermoplasty procedure codes effective January 1, 2013.

Boston Scientific will participate in the healthcare conference on September 12. Learn how to watch the webcast or replay.

System is the world's first rechargeable SCS device; approval provides physicians with an additional diagnostic option for patients with chronic intractable pain.

World's first rechargeable SCS device approved for peripheral nerve stimulation for patients with chronic intractable pain of the trunk.

Newly revised European Society of Cardiology guidelines include LAA closure devices.

PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...

Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...